PERSON-CENTERED DIAGNOSIS: PRINCIPLES AND PRACTICE It is more
important to know what person has the disease than which disease
the person has. —William Osler The purpose of this paper is to present an organizational structure for assessment of patients as unique individuals, an approach I have called person-centered diagnosis.[1] The goal of Person-Centered Diagnosis is to enable healers to develop individualized treatment plans that are based upon an understanding of the physiological, environmental, and psychosocial contexts within which each person's illnesses or dysfunctions occur. You must start by eliciting all of the patient's concerns. In actively listening to the patient's story, you attempt to discover the antecedents, triggers and mediators that underlie symptoms, signs, illness behaviors, and demonstrable pathology. Integrated medicine is based upon treatment that is collaborative, flexible, and focused on the control or reversal of each person's individual antecedents, triggers and mediators, rather than the treatment of disease entities. Eliciting the
Patient's Story The first step in patient-centered care is eliciting the patient's story in a comprehensive manner. It is the integrative practitioner's job to know not just the ailments or their diagnoses, but the physical and social environment in which sickness occurs, the dietary habits of the person who is sick (present diet and pre-illness diet), his beliefs about the illness, the impact of illness on social and psychological function, factors that aggravate or ameliorate symptoms, and factors that predispose to illness or facilitate recovery. This information is necessary for establishing an integrated treatment plan. The importance of understanding the patient's experience of his/her illness cannot be overemphasized. Extensive research on doctor-patient interactions indicates that doctors who fail to pay attention to the patient's concerns miss important clinical information. The conventional diagnostic paradigm, differential diagnosis, leads doctors to ignore or denigrate information that patients consider important, or that influences individual prognosis.[2],[3],[4] Not only does this ignorance impair the effectiveness of treatment,[5] it generates considerable dissatisfaction among patients.[6],[7],[8] Extensive research done within the context of conventional medical care reveals what most patients know: doctors do not pay enough attention to what their patients have to say. A study done at the University of Rochester found that most patients have three reasons for visiting a physician, are interrupted within eighteen seconds of starting to tell their stories, and never get the chance to finish.[9] Although doctors excuse this behavior by citing lack of time, it would have taken an average of one minute and rarely more than three minutes for a complete list of problems to be elicited. Even when doctors know what their patients' concerns are, they typically ignore them.[10] Most patients have different ideas about their illnesses than their doctors and some form of clarification or negotiation is needed for an effective therapeutic alliance to be established.[11] A study that carefully analyzed taped transcripts of visits to a medical clinic found that patients attempted to clarify or challenge what their doctor had said in 85% of the visits. Their requests were usually ignored or interrupted.[12] Understanding the patient's perspective allows the doctor to work in a collaborative way with patients, giving information that helps the patient make healthful choices.[13] The more information the patient receives from the doctor and the more actively the patient is involved in making decisions about treatment, the higher the level of mutual satisfaction, and the better the clinical outcome.[14],[15],[16],[17],[18] A systematic review of randomized clinical trials and analytic studies of physician-patient communication confirmed a positive influence of quality communication on health outcomes.[19] Such a collaborative relationship depends upon the practitioner recognizing and acknowledging the patient's experience of the illness. Useful questions to ask include: · How are you hoping that I can help you today? · What do you believe is the source of your problems? · What kind of treatment are you looking for? · What do you most fear about your illness? · What impact have your symptoms had on your life? Organizing and
Analyzing the Patient's Story What modern science has taught us about the genesis of
disease can be represented by three words: triggers, mediators and antecedents.
Triggers are discrete entities or events that provoke
disease or its symptoms.
Microbes are an example. The greatest scientific discovery of the nineteenth
century was the microbial etiology of the major epidemic diseases. Triggers are
usually insufficient in and of themselves for disease formation, however. Host
response is an essential component. Identifying the biochemical mediators that
underlie host responses was the most productive field of biomedical research
during the second half of the twentieth century. Mediators, as the word implies, do not "cause" disease.
They are intermediaries that contribute to the manifestations of disease. Antecedents are factors that predispose to acute or chronic illness.
For a person who is ill, they form the illness diathesis. From the perspective
of prevention, they are risk factors. Knowledge of antecedents has provided a
rational structure for the organization of preventive medicine and public
health. Medical genomics seeks to better understand disease by identifying the
phenotypic expression of disease-related genes and their products. The
application of genomic science to clinical medicine requires the integration of
antecedents (genes and the factors controlling their expression) with mediators
(the downstream products of gene activation). Mediators, triggers, and
antecedents are not only key biomedical concepts, they are also important
psychosocial concepts. In person-centered diagnosis, the mediators, triggers
and antecedents for each person's illness form the focus of clinical investigation. Antecedents and the Origins of
Illness Understanding the antecedents of
illness helps the physician understand the unique characteristics of each
patient as they relate to his current health status. Antecedents may be thought
of as congenital or developmental. The most important congenital factor is
gender: women and men differ markedly in susceptibility to many disorders. The
most important developmental factor is age: what ails children is rarely the
same as what ails the elderly. Beyond these obvious factors lies a diversity as
complex as the genetic differences and separate life experiences that
distinguish one person from another. Congenital factors may be
inherited or acquired in utero. They can most readily be evaluated from
a comprehensive family history, including mother's health before and during
pregnancy. Genomic analysis, which is now commercially available, can
supplement the family health history as a tool for investigating unique
nutritional needs or individual variability in sensitivity to environmental
toxins.[20],[21]
The commonest single gene disorders in North America, celiac disease and
hemochromatosis, may be confirmed by the presence of genetic markers, but
should first be suspected from abnormalities in routine lab tests. Elevated
serum ferritin concentration or transferrin saturation should prompt genetic
testing for the alleles associated with hereditary hemochromatosis.[22]
Increased small intestinal permeability, as measured by the inexpensive,
non-invasive and under-utilized lactulose/mannitol challenge test, has a
sensitivity approaching 100% for untreated celiac disease.[23]
Abnormal intestinal permeability should prompt the measurement of
celiac-specific immune markers in patients with chronic fatigue, autoimmune
disorders, or chronic gastrointestinal complaints of any type. Normal intestinal permeability in
patients consuming gluten almost always excludes celiac disease as a
consideration; however, this may not necessarily be the case for other
gluten-sensitive disorders. Because celiac disease and gluten-sensitive
disorders are common, have protean manifestations, and can be well controlled
by nutritional interventions, intestinal permeability should be a routine
component of the laboratory testing for antecedents of illness. The treatment
of choice for frank hemochromatosis is phlebotomy, but mild iron overload
without frank hemochromatosis is more common than the full-blown disease. These
patients generally have only one of the alleles associated with the disease,
but have elevated transferrin saturation and/or ferritin. They are not treated
with phlebotomy, and should be treated with dietary interventions. They should
not take iron or vitamin C supplements, because vitamin C reduces iron to its
more toxic form. Some familial disorders may
reflect intra-uterine rather than genetic influences. Twin studies of
hypertension, for example, indicate a higher concordance for blood pressure
between identical twins with a common placenta than identical twins with
separate placentas.[24]
Presumably, the shared placenta mediates subtle nutritional influences that
affect a tendency toward chronic illness in adulthood. Post-natal developmental factors
that govern the predisposition to illness include nutrition, exposure to
toxins, trauma, learned patterns of behavior, and the microbial ecology of the
body. Sexual abuse in childhood, for example, is associated with an increased
risk of abdominal and pelvic pain syndromes among women.[25],[26]
Recurrent otitis media increases the risk of a child developing attention
deficit disorder,[27],[28]
an effect that is not associated with hearing loss but may result from the
effects of antibiotics on the microbial ecology of the gut. Precipitating events are critical
antecedents that closely precede the development of chronic illness. They
represent a boundary in time: before this event, the person was considered
healthy; since the event, the person has become a patient. Understanding the
nature of the precipitating event may aid in unraveling the triggers and
mediators that maintain the state of illness. The commonest precipitating
events among my patients are a period of severe psychosocial distress, an acute
infection (sometimes treated with antibiotics), exposure to environmental
toxins at work or home, or severe nutrient depletion related to illness or
crash dieting. Useful questions for uncovering precipitating events include: · When is the last time you felt really well for more than a
few days at a time? · During the six months preceding that date, did you
experience any illness or major stress, change your use of medication or
dietary supplements, or make any significant life changes? Other publications of this author
present cases in which cryptogenic illness was found to be precipitated by
foreign travel, antibiotic use, dietary changes,[29]
smoldering infection, or the illness of a spouse.[30] Triggers and the Provocation of
Illness A trigger is anything that
initiates an acute illness or the emergence of symptoms. The distinction
between a trigger and a precipitating event is relative, not absolute; the
distinction helps organize the patient's story. As a general rule, triggers
only provoke illness as long as the person is exposed to them (or for a short
while afterward), whereas a precipitating event initiates a change in health
status that persists long after the exposure ends. Common triggers include
physical or psychic trauma, microbes, drugs, allergens, foods (or even the act
of eating or drinking), environmental toxins, temperature change, stressful life
events, adverse social interactions, and powerful memories. For some
conditions, the trigger is such an essential part of our concept of the disease
that the two cannot be separated; the disease is either named after the trigger
(e.g., "Strep throat") or the absence of the trigger negates the
diagnosis (e.g., concussion cannot occur without head trauma). For chronic
ailments like asthma, arthritis, or migraine headaches, multiple interacting
triggers may be present. All triggers, however, exert their effects through the
activation of host-derived mediators. In closed head trauma, for example,
activation of NMDA receptors, induction of nitric oxide synthase (iNOS), and
liberation of free intra-neuronal calcium determine the late effects.
Intravenous magnesium at the time of trauma attenuates severity by altering the
mediator response.[31],[32]
Sensitivity to different triggers often varies among persons with similar
ailments. A prime task of the integrative practitioner is to help patients
identify important triggers for their ailments and develop strategies for
eliminating them or diminishing their virulence. Although the identification and
elimination of triggers is not a foreign concept in conventional medicine, many
physicians neglect the search. A study was conducted by telephone in which
practicing physicians were asked how they would treat a new patient with
abdominal pain, who had a recent diagnosis of gastritis made by a specialist in
another town. Almost half were ready to put the patient on acid-lowering
therapy without asking about the patient's use of aspirin, alcohol or tobacco,
all of which are potential triggers for gastritis. The authors of the study
concluded, "In actual practice, ignoring these aspects of the patient may
well have reduced or even negated the efficacy of other therapeutic plans
implemented."[33]
Mediators and the Formation of
Illness
A mediator is anything that
produces symptoms, damage to tissues of the body, or the types of behaviors
associated with being sick. Mediators vary in form and substance. They may be
biochemical (like prostanoids and cytokines), ionic (like hydrogen ions),
social (like reinforcement for staying ill), psychological (like fear), or
cultural (like beliefs about the nature of illness). A list of common mediators
is presented in Table 1. Illness in any single person usually involves multiple
interacting mediators. Biochemical, psychosocial, and cultural mediators
interact continuously in the formation of illness. Table 1 Common Illness Mediators
Cognitive/emotional mediators
determine how patients appraise symptoms and what actions they take in response
to that appraisal.[34]
They may even modulate the symptoms themselves. People in pain, for example, experience
more pain when they fear that pain control will be inadequate than when they
believe that ample pain management is available.[35] Perceived self-efficacy (the
belief in one's ability to cope successfully with specific problems) is a
cognitive mediator that determines coping with illness. People with a high
degree of health self-efficacy usually adapt better to chronic disease,
maintaining higher levels of activity, requiring lower doses of pain
medication, adopting healthier lifestyles, and cooperating with prescribed
therapies, compared to people with low self-efficacy.[36]
Self-management education is designed to enhance self-efficacy,[37]
and has been shown to improve the clinical outcome for patients with several
types of chronic disease, including asthma,[38]
arthritis,[39],[40],[41]
and diabetes.[42]
The biochemical mediators of disease listed in Table1 are best known for their ability to promote cellular damage. Most are organized into circuits and cascades that sub-serve homeostasis and allostasis. In these networks, each mediator is multi-functional and most functions involve multiple mediators, so that redundancy is the rule, not the exception. The most striking characteristic of biochemical mediators is their lack of disease specificity. Each mediator can be implicated in many different, apparently unrelated diseases, and every disease involves multiple chemical mediators in its formation. Mediator networks that regulate
inflammatory and neuroendocrine stress responses have been the subject of
intensive research with important clinical implications. Comprehensive reviews
have appeared elsewhere.[43],[44],[45],[46]
Within the framework of integrated medicine, a key feature of biochemical
mediators is the natural rhythm of mediator activity, which is strongly
influenced by the common components of life: diet, sleep, exercise, hygiene,
social interactions, solar and lunar cycles, age, and sex. Aging, illness, and
chronic psychological distress up regulate activity of the inflammatory and
neuroendocrine-stress response networks. Regular physical activity down
regulates both. Integrating the Patient's Story After listening to the concerns
that led each patient to seek a consultation in integrated medicine, the
clinician makes a series of distinctions: 1)
For patients whose
main concern is optimal health and prevention, ask about present and past
health problems and the family health history. If these supply no indication of
illness susceptibility, then turn your attention to risk factors for future
illness: weight, fitness, type and level of physical activity, dietary pattern,
sleep habits, use of alcohol, drugs, tobacco, firearms, environmental exposures
at home and work, travel, sources of stress and pleasure, degree of involvement
with others, spiritual beliefs and practices, sexual relationships, hopes and
fears for the future. 2)
For patients with an
active health problem, always ask, "What was your health like before this
problem began?" An intake questionnaire that asks about previous health
problems is also helpful, because it gathers information in a different fashion
concerning what the patient was like prior to the present illness. Such a tool
is condition-specific, not open-ended. The two approaches complement one
another. a)
Some patients will say
that they were really healthy prior to their present illness. In that case,
look for a precipitating event. If you or the patient can identify one, then
ask about ongoing triggers that bear some relationship to the precipitating
event. For example: if the precipitating event was marital or job stress, focus
on stress-related psychological triggers. If the precipitating event was an
environmental exposure, focus on on-going exposures to volatile chemicals or
mold. b)
The most challenging
patients will usually indicate that their health was poor even before their
present illness. In that case, take a detailed, chronological history from
birth to the present that includes information about early life experience
(including illness, injury and abuse), school and work performance, diet, drug
and medication use, leisure activities, travel, family life, sexual
experiences, habits, life stressors and places of residence. Because gathering
this data can be very time consuming, a self-administered questionnaire
completed by the patient before the interview may help to prompt responses and
improve memory of remote events. For many patients with complex, chronic health
problems, it may be useful to take a detailed life history before
seeking detailed information about present symptoms. Problems that emerge from
such a review have to be addressed for a successful outcome of treatment.
Dealing with the present concerns by themselves almost never succeeds for
patients in this group. Whatever rapport you establish
with patients initially, maintaining the therapeutic relationship usually
depends upon significant improvement in symptoms or in a sense of well being
within a few days to a few weeks of the initial evaluation. Addressing the
triggers that provoke symptoms and helping the patient decrease exposure to
them most efficiently achieve this. When triggers cannot be identified or
avoided, then symptomatic improvement must rest on control of mediator
activation. A combination of the two will usually produce the most satisfactory
long-term benefits. Assessment of Triggers A comprehensive search for
triggers requires that you know the following about your patient: each
drug—prescription, over-the-counter or recreational—that the patient has used
and when; nutritional habits and each dietary supplement used and when; what
effects the patient noted from the use of each substance; sources of
stress—life events, environmental exposures, thoughts or memories, and social
interactions—and when they occurred in relation to symptoms. Elicit the
patient's own ideas about possible triggers by asking, "What do you think
causes or aggravates your symptoms?" The patient's observations may be
insightful and accurate in ascribing causality. Of course the patient’s—and the
clinician’s—observations can also mislead, or focus on non-essential factors.
Teach patients to challenge their own observations by looking for consistency
and replicability, wherever possible. Suggest alternative theories for the
patient to consider and explain that the search for triggers works best as a
collaborative effort between patient and doctor. The patient's ability to
recognize triggers is an important step in self-care. Food and environment supply
important triggers for the practice of integrated medicine. Food intolerance is
a very common phenomenon,
reported by thirty-three per cent of the population in one large study.[47]
Relatively few of these reactions (4-14%) are due to true food allergies. Most
food intolerance has no clear immunologic basis. Mechanisms include sensitivity to the pharmacological effect of
alkaloids, amines or salicylates in food.[48],[49],[50],[51]Histamine
poisoning from scombroid fish and tyramine-induced headache are dramatic
examples.[52]
Although most food intolerance is short-lived, severe chronic
illness can occur, and the food trigger may elude identification unless the
physician starts the investigation with a high index of suspicion. Gluten
intolerance, with its protean manifestations, is probably the best example.
Affecting about two per cent of people of European ancestry,[53]
gluten intolerance is common and often unrecognized. In addition to being the
essential trigger for celiac disease, gluten sensitivity may be manifest in
patients with neurological disorders of unknown cause,[54]
cerebellar degeneration,[55]
dermatitis herpetiformis,[56]
failure to thrive,[57]
pervasive developmental delay,[58]
inflammatory arthritis,[59],[60],[61],[62],[63]
psoriasis,[64],[65]
Sjögren’s syndrome,[66],[67]
and schizophrenia.[68],[69]
The different presentations of gluten sensitivity may derive from genetic
differences among affected patients.[70]
Published studies on food
intolerance and your patients' symptoms may be found through the National
Library of Medicine. If the patient has a disease diagnosis, an Internet search
may reveal previously observed associations between specific foods and the
patient's condition. Access PubMed over the Internet (www.pubmed.gov) and run a
search that cross-references the name of the patient's condition with
"Hypersensitivity, Food" and also with "Food, adverse
reactions.” Both of these are Medline Subject Headings (MESH). There is no MESH
listing for "Food Allergy" or "Food Intolerance.” Your search
will be more efficient if you list the patient's condition as it appears in
MESH. A negative search does not eliminate food intolerance as a trigger for
the condition being searched, but the number of positive findings may surprise
you.[1] Health effects of ambient air
quality are as important as those of foods. Numerous studies conducted in U.S.
cities demonstrate a close correlation between fine particle air pollution and
daily mortality rates, even at levels of pollution considered safe by the World
Health Organization.[71]
In the industrialized world, most people spend most of their time indoors, and
indoor air pollution has become a serious cause of morbidity. Studies using
experimental chambers have shown that volatile organic compounds (VOCs)
released from building materials, furnishings, office machines, and cleaning
products can cause irritation of the respiratory system in humans and animals
at levels which are one hundred times weaker than permissible exposure levels
or the World Health Organization Indoor Air Guidelines.[72],[73],[74]
Controlled experiments with people who describe themselves as sensitive to VOCs
confirm that VOC exposure causes headache, fatigue, and difficulty
concentrating. People who deny such sensitivity also experience symptoms but do
not experience mental impairment when exposed. Air samples of buildings with
and without “sick building” complaints have established an association between
VOC exposure and human sickness.[75],[76],[77],[78] A questionnaire can elicit important
information about environmental exposures at home and at work. The open-ended
question, "Has your work or home environment been a concern to you?"
should be accompanied by a checklist of potential exposures. Microbial triggers for chronic
illness present a particular challenge, as exemplified by the many facets of Helicobacter pylori infection.
Originally isolated from the gastric mucosa of patients with gastritis and
peptic ulcer disease, H. pylori has
been implicated in the pathogenesis of NSAID gastropathy,[79]
gastric carcinoma,[80]
lymphoma,[81]
and a variety of extra-digestive disorders, including ischemic heart disease,[82]
ischemic cerebrovascular disorders,[83]
rosacea,[84]
Sjögren’s syndrome,[85]
Raynaud's syndrome,[86]
food allergy,[87]
vitamin B12 deficiency,[88]
and open angle glaucoma.[89]
For elderly patients with open angle glaucoma and incidental H. pylori infection of the stomach,
eradication of H. pylori by antibiotics was associated with improved control of
glaucoma parameters at two years.[90]
The mechanism by which H. pylori
aggravates open-angle glaucoma is unknown, but may result from the ability of H. pylori colonization of the gastric
tract to trigger the local and systemic release of platelet-activating factor,
inflammatory cytokines, and vasoactive substances. In the case of untreated H. pylori infection, non-invasive
screening tests, including serum antibodies, stool antigens, and C-14 breath
testing, are available. For other types of infection, inquiring about the
previous response of a given symptom or symptom complex to antibiotics may be
useful. In 1988, physicians at the University of Minnesota conducted a study in
which they administered intravenous cephalosporins to patients with various
types of arthritis who also manifested antibodies to Borrelia burgdorferi. Most of these patients were not thought to
have Lyme disease. Some met diagnostic criteria for rheumatoid arthritis, some
for osteoarthritis, and some for spondyloarthropathies. The response to
antibiotics was quite variable and ranged from no response to dramatic and
sustained improvement. The authors noted that improvement in arthritis
following antibiotics was not related to the patient's clinical diagnosis or
the level of anti-Borrelia antibody.
The best predictor of a positive response to the experimental treatment was a
previous history of improvement of arthritis associated with the use of
antibiotics.[91] The most comprehensive way to ask
the antibiotic question is: "During the time you have had symptom X, have
you taken antibiotics for any reason? Which antibiotic? Did symptom X change
while you were taking the drug?" Among patients with chronic diarrhea of
unknown cause, for example, some will report that their gastrointestinal
symptoms improved when taking a specific antibiotic; others will report that
they worsened. The first case suggests that bacteria or protozoa sensitive to
the antibiotic may be causally related to the patient's gastrointestinal
problems. Repeating the antibiotic prescription can establish if this response
is replicable. If so, therapy can focus on treating the microbe and
understanding why a single course of antibiotics was ineffective. The second
case suggests that depletion of bacteria by antibiotics and concomitant
increase in antibiotic-resistant organisms, including yeasts, may be
contributing to diarrhea, and treatment can focus on restoration of normal
intestinal flora. Assessment of Psychosocial Mediators Useful questions for eliciting a
person's beliefs about his/her illness are: "What
do you think has caused your problem?" "What
do you most fear about your problem?" "How
much control do you think you have over your symptoms?" Useful questions for eliciting
information about the nature and sources of social support include: "Are
there people in whom you can confide?" "How
satisfied are you with your marriage/family/friends/social life?” "How
much support do you receive in dealing with your health problems?" "How
often do you feel loved or cared for?" Assessment of Biochemical
Mediators Understanding the biochemical alterations associated with
a conventional disease diagnosis can be helpful in
understanding the biochemical mediators of each person's illness. Inflammation
is believed to play a critical role not only in response to infection and in
the classic inflammatory diseases, but also in the pathogenesis of coronary
artery disease, diabetes, cancer, depression, and the negative health effects
associated with obesity and with aging.[92],[93],[94],[95],[96],[97],[98]
The orchestration of mediator signals in the inflammation and
neuroendocrine-stress networks, as they interact with one another, is critical
for normal physiological functions (e.g., the architecture of sleep, the repair
of injury, and the response to infection), and for the dysfunctional physiology
central to the pathogenesis of most of the major chronic diseases.[99],[100],[101] Most chronic disease is associated
with chronic inflammation, but the patterns of immune response that underlie
inflammation are not always the same. Patients with Type 1 diabetes mellitus,
Crohn's disease or any other disorder categorized by granuloma formation or
excessive cell mediated immune responses are likely to have an immune response
to common triggers in which the Th1 component is up regulated and not subject
to the normal down regulation provided by Th2 activity. Their mediator response
to inflammatory stimulation produces excessive levels of gamma-interferon
(g-IFN) and interleukin-12 (IL-12), key Th1-related cytokines.[102]
Patients with severe depression often show a loss of negative feedback in the
HPA axis. Urinary free cortisol is elevated;the diurnal pattern may be
disrupted, with increased PM cortisol secretion and blunting of dexamethasone
suppression. This phenomenon appears to be driven at the level of the
hypothalamus, not the adrenals, because spinal fluid corticotrophin releasing
hormone (CRH) is elevated.[103]
Several groups of researchers in the late 1990s speculated that impaired
synaptic function due to a deficit of omega-3 fatty acids may contribute to the
CNS dysfunction of patients with depressive illness[104],[105],[106],[107]
(although some large recent studies do not show the same patterns[108],[109]).
Omega-3 fatty acid levels tend to be lower in blood samples than in control
populations. The key component appears to be eicosapentaenoic acid (EPA). To utilize the vast database of
available information about biochemical disease mediators, integrative
clinicians should consider three strategies. First, maintain up-to-date
knowledge of disease pathophysiology by reading reviews in mainstream journals on
mechanisms of disease or on specific mediators. In reading these, pay special
attention to the types of mediators mentioned and their functions within the
networks that involve inflammation, oxidative stress, and neuroendocrine
balance. Second, attend workshops and courses that emphasize integrative
physiology, sponsored by institutions like the New York Academy of Sciences.
Third, employ knowledge of the commonest biochemical imbalances in chronically
ill North Americans and the influence of diet, nutrition, and dietary
supplements on these imbalances. Treatment Planning An
integrated treatment plan should be collaborative and dynamic. Collaborative
means that patient and practitioner work together to set goals and priorities.
Dynamic means that the treatment plan is adjusted as needed in response to
feedback. Your knowledge of the patient's beliefs about his/her illness and
perceived self-efficacy are essential for collaborative treatment. An appropriate therapeutic intervention for dysfunctional
beliefs is the giving of information. Patients have an intense need for
explanations about the causes of their diseases.[110]
They want to know how they came to be sick, so that they can attach some
meaning to the illness,[111]
what to expect from the illness, and what they can do to relieve symptoms or
speed recovery. Information of this
type can reduce anxiety (even
when the diagnosis itself is frightening), increase feelings of personal
control, and improve the ability to cope with pain. People change their
behaviors more readily when they receive information about the importance and
the nature of the changes they need to make, help with setting goals, and
measuring progress. The kind of information needed is personal, not
statistical. It must answer the question, "What can I do?" The physician can help patients
who are suffering from isolation by calling this isolation to the attention of
family members or friends, or by attempting to connect the patient with a
support group or community agency. Possibly, there is nothing that can be done
to relieve the patient's isolation, but the doctor's awareness and
acknowledgment of it can be important to the patient and serve to enhance the
therapeutic relationship.[112]
If potential triggers have been
identified, an assessment of the patient's ability to control exposure to them
is important. For patients who are reluctant to make major dietary or
environmental changes, explain that each avoidance is an experiment that the
patient can direct with your guidance. If eliminating foods (and reintroducing
those foods as a challenge) has no effect on symptoms or measurable physiologic
parameters do not encourage the patient to persist in the avoidance of those
foods, whatever the results of in vitro
allergy tests may be. The patient will have enough work to do following a
healthy diet. Food intolerance is only meaningful if its effects can be
demonstrated in real life. For microbial triggers, the
decision to use prescription antimicrobial drugs or natural products with
antimicrobial activity may require negotiation. If the situation is not
critical, it is usually worthwhile honoring the patient's preferences and
intuition. Understanding the ways in which
mediators are modulated by diet enables creative nutritional therapies to be applied.
Salicylic acid, the major metabolite of aspirin, suppresses activation of the
nuclear transcription factor NF-kB, an anti-inflammatory effect that is
independent of cyclooxygenase inhibition[113]
and may be responsible for some effects of low-dose aspirin therapy.[114]
Vegetables are rich sources of natural salicylates and vegetarians may have
serum concentrations of salicylic acid as high as those of people ingesting 75
mg of aspirin a day.[115] Dietary fatty acids may have
profound effects on the network of inflammatory mediators, altering prostanoid
synthesis, PPAR activity, and the response to cytokines like IL-1.[116],[117],[118]
They have subtler effects on the neuroendocrine-stress response network,
modulating neuronal responses to serotonergic and adrenergic transmission.[119]
Therapy with omega-3 fatty acids
provides an excellent example of
nutritional modulation of
disease activity though alteration of
biochemical mediators.[120]
Three principles can guide this type of therapy. The first utilizes knowledge
of the pathophysiology of specific inflammatory and CNS disorders. Using this
model, omega-3 therapy has been successfully applied to the treatment of
patients with rheumatoid arthritis,[121]
inflammatory bowel disease,[122]
coronary artery disease,[123]
peripheral vascular disease,[124]
dysmenorrhea,[125]
cystic fibrosis,[126]
migraine headaches,[127]
schizophrenia,[128],[129]
atopic eczema,[130]
and multiple sclerosis.[131],[132]
Because the fatty acid composition of the contemporary Western diet differs
significantly from Paleolithic and ancestral diets, reflecting a marked
decrease in omega-3 consumption relative to total fat, the response of so many
unrelated disorders to EFA supplementation may indicate that EFAs are not
merely working as nutriceutical agents, but that EFA dietary status is
important for disease pathogenesis. The second method rests upon the
clinical evaluation of an individual’s fatty acid status using clinical
parameters that are independent of disease activity. Prasad has stated that the
best test for nutritional adequacy is a functional test.[133]
Determine a parameter to follow and measure how administration of the
nutrient(s) in question affects that parameter. This method can be applied to
the use of EFA therapy in clinical practice. Stevens et al., studying boys with
ADHD and a randomly selected population of schoolchildren, found a correlation
between low concentrations of omega-3 EFAs, learning and behavior problems, and
symptoms associated with EFA deficiency (thirst, dry skin, and dry hair).[134],[135]
Evaluating the presence of these symptoms in patients and observing how they
change with EFA supplementation is a quick guide to EFA status that may be used
clinically to evaluate the EFA contribution to mediator imbalance. This
author's method for doing this has been described elsewhere.[136]
Finally, it is possible to measure the levels of fatty acids in plasma and
erythrocyte phospholipids, although guidelines for level of change in fatty
acid profiles needed to produce a known clinical effect have only been
reported for patients with rheumatoid arthritis, in whom clinical improvement
requires that eicosapentanoic acid (EPA) account for 5% of fatty acids in
plasma phospholipids.[137] The successful application of
nutritional therapies, especially dietary interventions, and other self-care
practices, as part of a therapeutic plan is very helpful in enhancing
self-efficacy among patients. Enhancement of self-efficacy should always be a
cardinal goal of treatment in integrated medicine. Summary Integrated medicine is essentially
patient centered, rather than disease centered. A structure is presented for
uniting a patient-centered approach to diagnosis and treatment with the fruits
of modern clinical science (which evolved primarily to serve the prevailing
model of disease-centered care). The core scientific concepts of disease
pathogenesis are antecedents, triggers, and mediators. Antecedents are factors,
genetic or acquired, that predispose to illness; triggers are factors that
provoke the symptoms and signs of illness; and mediators are factors,
biochemical or psychosocial, that contribute to pathological changes and
dysfunctional responses. Understanding the antecedents, triggers and mediators
that underlie illness or dysfunction in each patient permits therapy to be
targeted to the needs of the individual. The conventional diagnosis assigned to
the patient may be of value in identifying plausible antecedents, triggers or
mediators for each patient, but is not adequate by itself for the designing of
patient-centered care. Applying the model of
Person-Centered Diagnosis to patients facilitates the recognition of
disturbances that are common in people with chronic illness. Diet, nutrition,
and exposure to environmental toxins play central roles in integrated medicine
because they may predispose to illness, provoke symptoms, and modulate the
activity of biochemical mediators through a complex and diverse set of
mechanisms. A patient's beliefs about health
and illness are critically important for self-care and may influence both
behavioral and physiological responses to illness. Perceived self-efficacy is
an important mediator of health and healing. Enhancement of patients'
self-efficacy through information, education, and the development of a
collaborative relationship between patient and healer is a cardinal goal in all
clinical encounters. References [1] Medical cybrarian Valerie Rankow ([email protected]) has assisted the author with this search strategy and with numerous other, more complex searches. [1] Galland L, "Person-Centered Diagnosis,” in Power Healing. New York:Random House, 1997, pp 52-97. [2] Reiser SJ. The era of the patient. Using the
experience of illness in shaping the missions of health care. JAMA.
1993;269:1012-1017. [3] Beckman HB, Frankel RM. The effect of physician
behavior on the collection of data. Ann Intern Med. 1984;101:692-696. [4] Frankel R. Talking in interviews: a dispreference for
patient-initiated questions in physician-patient encounters. In Studies in
Ethnomethodology and Conversation Analysis. No. 1. G Psathas, ed. The
International Institute for Ethnomethodology and Conversation Analysis and
University Press of America. Washington D.C. 1990:231-262. [5] Roter DL, Hall JA. Physician interviewing styles and
medical information obtained from patients. J Gen Intern Med. 1987;2(5):325-29. [6] Bartlett EE, Grayson M, Barker R, Levine DM, Golden
A, Libber S. The effects of physician communications skills on patient
satisfaction;recall and adherence. J Chronic Dis. 1984;37:755-64. [7] Smith RC, Hoppe RB. The patient's story: integrating
the patient- and physician-centered approaches to interviewing. Ann Intern Med.
1991;115:470-477. [8] Sanchez-Menegay C, Stalder H. Do physicians take into
account patients' expectations? J Gen Intern Med. 1994;9:404-406. [9] Beckman DB, Frankel RM The effect of physician
behavior on the collection of data. Ann Intern Med. 1984;101:692-696. [10] Sanchez-Menegay C and Stalder M. Do physicians take into account patients' perspectives? J Gen Intern Med. 1994;9:404-406. [11] Freidin RB, Goldin L, Cecil RR. Patient-physician concordance in problem identification in the primary care setting. Ann Intern Med. 1980;93(3):490-93. [12] Tucket D. Meetings Between Experts: An Approach to Sharing Ideas in Medical Consultations. London and New York, Tavistock Publications, 1985. [13] Hall JA, Roter DL, and Katz NR, Meta-analysis of correlates of provider behavior in medical encounters. Med Care. 1988;28:657-75. [14] Kaplan SH, Greenfield S, Ware JE Jr. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care. 1989;27 Suppl 3:S110-127. [15] Ades PA, et al, Predictors of cardiac rehabilitation participation in older coronary patients. Arch Intern Med. 1992;152:1033-35. [16] Mullen PD. Efficacy of psychoeducational interventions on pain, depression and disability in people with arthritis: a meta-analysis. J Rheumatol. 1987;14 Suppl 15:33-39. [17] Wilson SR, et al. A controlled trial of self-management education for adults with asthma. Am J Med. 1993;94:564-576. [18] Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum. 1993;36:439-46. [19] Teutsch C. Patient-doctor communication. Med Clin North Am. 2003;87(5):1115-45. [20] Guengerich FP. Functional genomics and proteomics applied to the study of nutritional metabolism. Nutr Rev. 2001;59:259-62. [21] Pennie W, Pettit SD, Lord PG. Toxicogenomics in risk assessment: overview of an HESI collaborative research program. Environ Health Perspect. 2004;112:417-19. [22] Pietrangelo A. Hereditary hemochromatosis--a new look at an old disease. N Engl J Med. 2004;350:2383-97. [23] Vogelsgang H, Schwarzenhofer M, Oberhuber G. Changes in gastrointestinal permeability in celiac disease. Dig Dis. 1998;16:333-36. [24] Phillips DW. Twin studies in medical research.
(letter) Lancet. 1993;342:52. [25] Romans S, Belaise C, Martin J, Morris E, Raffi A. Childhood abuse and later medical disorders in women. An epidemiological study. Psychother Psychosom. 2002;71(3):141-50. [26] Lampe A, Solder E, Ennemoser A, et al. Chronic pelvic pain and previous sexual abuse. Obstet Gynecol. 2000;96(6):929-33. [27] Hagerman RJ, Falkenstein AR. An association between recurrent otitis media in infancy and later hyperactivity. Clin Pediatr (Phila). 1987;26(5):253-57. [28] Adesman AR, Altshuler LA, Lipkin PH, Walco GA. Otitis media in children with learning disabilities and in children with attention deficit disorder with hyperactivity. Pediatrics. 1990;85(3):442-6. [29] Galland, L. A New Definition of Patient-Centered Medicine. In Integrative Medicine, Principles for Practice. Edited by B. Kligler and R. Lee, 2004. New York, McGraw Hill, pp 71-101. [30] Galland, L. Power Healing. New York:Random House, 1997, pp 52-114. [31] Cernak I, Savic VJ, Kotur J, et al. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma. 2000;17(1):53-68. [32] Vink R, Nimmo AJ, Cernak I. An overview of new and novel pharmacotherapies for use in traumatic brain injury. Clin Exp Pharmacol Physiol. 2001;28(11):919-921. [33] Avorn J, Everitt
DE and Baker MW. The neglected medical
history and therapeutic choices for abdominal pain: A nationwide study of 799
physicians and nurses. Arch Intern Med. 1991;151: 694-98. [34] Kleinman A, Eisenberg L, Good B. Culture, illness and
care. Clinical lessons from anthropologic and cross-cultural research. Ann
Intern Med. 1978;88:251-58. [35] O'Leary A. Self-efficacy and health. Behav Res Ther.
1985;23(4):437-51. [36] Holden G. The relationship of self-efficacy
appraisals to subsequent health-related outcomes: a meta-analysis. Soc Work
Health Care. 1991;16:53-93. [37] Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA. 2002;288:2469-75. [38] Wilson SR, Scamagas P, German DF, et al. A controlled
trial of two forms of self-management education for adults with asthma. Am J
Med. 1993;94:564-76. [39] Mullen PD, LaVille EA, Biddle AK, Lorig K. Efficacy
of psychoeducational interventions on pain, depression, and disability in
people with arthritis: a meta-analysis. J Rheumatol. 1987;14 (suppl 15):33-39. [40] Schiaffino KM, Revenson TA, Gibofsky A. Assessing the impact of self-efficacy beliefs on adaptation to rheumatoid arthritis. Arthritis Care Res. 1991;4:150-57. [41]
Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for
self-management in patients with chronic arthritis has sustained health
benefits while reducing health care costs. Arthritis Rheum. 1993;36:439-46. [42] Litzelman DK,
Slemenda CW, Langefeld CD, et al. Reduction
of lower extremity clinical abnormalities in patients with non-insulin
dependent diabetes mellitus. A randomized, control trial. Ann Intern Med.
1993;119:36-41. [43]Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am. 2001;30:695-728. [44] Miller DB, O'Callaghan JP. Neuroendocrine aspects of the response to stress. Metabolism. 2002;51(6 Suppl 1):5-10. [45] Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol. 2001;79:350-57. [46] Chikanza IC, Grossman AB. Reciprocal interactions between the neuroendocrine and immune systems during inflammation. Rheum Dis Clin North Am. 2000;26:693-71. [47]
Bender AE, Matthews DR. Adverse reactions to foods. Br J Nutr. 1981;46:403-7. [48] Moneret-Vautrin DA. Food antigens and additives. J Allergy Clin Immunol. 1986;78:1039-46. [49] Kniker WT, Rodriguez M. Non-IgE mediated and delayed adverse reactions to food or additives. In Handbook of Food Allergies, ed. JC Breneman, 1987, New York, Marcel Dekker, pp 125-161. [50] Perry CA, Dwyer J, Gelfand JA, et al. Health effects of salicylates in foods and drugs. Nutr Rev. 1996;54(8):225-40. [51] Lovenberg W. Some vaso- and psychoactive substances in food: amines, stimulants, depressants and hallucinogens. In Toxicants Occurring Naturally in Foods. (2nd Ed). Eds:Committee on Food Protection, Food & Nutrition Board, National Research Council. Natl. Acad. Sci. Press. Washington DC. 1973, pp 170-188. [52]
Somogyi JC. Natural toxic substances in food. World Rev Nutr Diet. 1978;29:42-59. [53] Catassi C, Ratsch IM, Fabiani E, et al. Coeliac disease in the year 2000: exploring the tip of the iceberg. Lancet. 1994;343:200-3. [54] Hadjivasssiliou M, Gibson A, Davies-Jones GAB, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet. 1996;347:369-71. [55] Hadjivasssiliou M, Grunewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet. 1998;352:1582-85. [56] Collin P, Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am J Clin Dermatol. 2003;4(1):13-20. [57] Wolff A, Berger R, Gaze H, et al. IgG, IgA and IgE gliadin antibody determinations as screening test for untreated coeliac disease in children, a multicentre study. Eur J Pediatr. 1989;148(6):496-502. [58] Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiol. 2002;46(2):76-84. [59] Ramos-Remus C, Bahlas S, Vaca-Morales O. Rheumatic features of gastrointestinal tract, hepatic, and pancreatic diseases. Curr Opin Rheumatol. 1997;9(1):56-61. [60] Falcini F, Ferrari R, Simonini G, et al. Recurrent monoarthritis in an 11-year-old boy with occult coeliac disease. Successful and stable remission after gluten-free diet. Clin Exp Rheumatol. 1999;17(4):509-11. [61] Kallikorm R, Uibo O, Uibo R. Coeliac disease in spondyloarthropathy:usefulness of serological screening. Clin Rheumatol. 2000;19(2):118-22. [62] Slot O, Locht H. Arthritis as presenting symptom in silent adult coeliac disease. Two cases and review of the literature. Scand J Rheumatol. 2000;29(4):260-63. [63] Bagnato GF, Quattrocchi E, Gulli S, et al. Unusual polyarthritis as a unique clinical manifestation of coeliac disease. Rheumatol Int. 2000;20(1):29-30. [64] Lindqvist U, Rudsander A, Bostrom A, et al. IgA antibodies to gliadin and coeliac disease in psoriatic arthritis.
Rheumatology (Oxford). 2002;41(1):31-37. [65] Michaelsson G, Gerden B, Hagforsen E, et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. Br J Dermatol. 2000;142(1):44-51. 66 Teppo AM, Maury CP. Antibodies to gliadin, gluten and reticulin glycoprotein in rheumatic diseases: elevated levels in Sjögren's syndrome. Clin Exp Immunol. 1984;57(1):73-78. [67] Collin P, Korpela M, Hallstrom O, et al. Rheumatic complaints as a presenting symptom in patients with coeliac disease. Scand J Rheumatol. 1992;21(1):20-23. [68] Dohan, FC. Is celiac disease a clue to the pathogenesis of schizophrenia? Ment Hyg. 1969;53(4):525-29. [69] Vlissides DN, Venulet A,
Jenner FA. A double-blind
gluten-free/gluten-load controlled trial in a secure ward population. Br J Psychiatry. 1986;148:447-52. [70] Karell K, Korponay-Szabo I, Szalai Z, et al. Genetic dissection between coeliac disease and dermatitis herpetiformis in sib pairs. Ann Hum Genet. 2002;66(6):387-92. [71] Schwartz J, Dockery DW. Particulate air pollution and
daily mortality in Steubenville, Ohio. Am J Epidemiol. 1992;135:12-19. [72] Schwartz J, Dockery DW. Increased mortality in
Philadelphia associated with daily air pollution concentrations. Am Rev Respir
Dis. 1992;145:600-4. [73] Dockery DW, Schwartz J,
Spenger JD. Air pollution and daily
mortality: association with particulates and acid aerosols. Environ Res.
1992;59:362-73. [74] Dockery DW, Pope A, Xu
X, et al. An association between air
pollution and mortality in six U.S. cities. N Engl J Med. 1993;329:1753-59. [75] Hodgson MJ, Frohlinger J, Permar E, et al. Symptoms
and microenvironmental measures in non-problem buildings. J Occup Med.
1991;35:527-33. [76] Hodgson MJ. Buildings & health. Health Environ
Dig. 1993;7:1-3. [77] Norback D, Torgen M, Edling C. Volatile organic
compounds, respiratory dust and personal factors related to the prevalence and
incidence of SBS in primary schools. Br J Ind Med. 1990;47:733-41. [78] Hodgson M. Field studies on the sick building
syndrome. In Sources of indoor air contaminants: Characterizing emissions and
health impacts. Tucker WG, Leaderer BP, Molhave L, Cain WS, eds. Ann N Y Acad
Sci. 1992;641:21-36. [79] Chan FK, To KF, Wu JCY, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet. 2002;359:9-13. [80] Uemara N, Okamoto S, Yamamoto S, et al. Helicobacter pylori and the development of gastric cancer. N Engl J Med. 2001;345:784-89. [81] Wotherspoon AC, Dogliani C, Diss TC, et al. Regression of primary low-grade B-cell lymphoma of mucosal-associated lymphoid tissue after eradication of Helicobacter pylori. Lancet. 1993;342:575-77. [82] Mendall MA, Goggin OM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71:437-39. [83] Markus HS, Mendel MA. Helicobacter pylori: a risk factor for ischemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psychiatry. 1998;64:104-7. [84] Szlachcic A, Sliwowski Z, Karczewska E, et al. Helicobacter pylori and its eradication in rosacea. Physiol Pharmacol. 1999;50:777-86.
[85] Aragona P, Magazzu G, Macchia G, et al. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren’s syndrome. J Rheumatol. 1999;26:1306-11. [86] Gasbarrini A, Franceschi F, Arnuzzi A, et al. Extradigestive manifestations of Helicobacter pylori gastric infection. Gut. 1999;45 (suppl):I9-I12. [87] Matysiak-Budnik T, Heyman M. Food allergy and Helicobacter pylori. J Pediatr Gastroenterol Nutr. 2002;34:5-12. [88] Kaptan K, Beyan C, Ural AU, et al. Helicobacter pylori: is it a novel causative agent in vitamin B12 deficiency? Arch Intern Med. 2000;160:1349-53. [89] Kountouras J, Mylopoiulos N, Boura P, et al. Relationship between Helicobacter pylori infection and glaucoma. Ophthalmology. 2001;108:599-604. [90] Kountouras J, Mylopoulos N, Chatzopoulos D, et al. Eradication of Helicobacter pylori may be beneficial in the management of chronic open-angle glaucoma. Arch Intern Med. 2002;162:1237-44. [91] Caperton EM, Heim-Duthoy KL, Matske GR, et al. Ceftriaxone therapy of chronic inflammatory arthritis: a double-blind placebo-controlled trial. Arch Intern Med. 1990;150:1677-82. [92] Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649-52. [93] Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;2823:2131-35. [94] Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26. [95] Abramson JL, Vaccarino V. Relationship between activity and inflammation among apparently healthy middle-aged and older adults. Arch Int Med. 2002;162:1286-92. [96] Maes M. Major depression and activation of the inflammatory response system. In Cytokines, Stress and Depression, edited by Danzer et al. Kluwer Academic/Plenum Publishers. New York. 1999, pp 25-46. [97] Shacter E, Weitzman SA. Chronic inflammation and
cancer. Oncology. 2002;16:217-26, 229. [98] Franceschi C, Ottaviani E. Stress, inflammation and
natural immunity in the aging process: a new theory. Aging (Milano). 1997;9(4
Suppl):30-31. [99] Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann N Y Acad Sci. 2002;966:290-303. [100] Petrovsky N. Towards a unified model of
neuroendocrine-immune interaction. Immunol Cell Biol. 2001;79:350-57. [101]
Jessop DS, Harbuz MS, Lightman SL. CRH in chronic inflammatory stress. Peptides. 2001;22:803-07. [102] Libby P. Inflammation:a common pathway in cardiovascular diseases. Dialogues Cardiovasc Med. 2003;8:59-73. [103] Wong ML, Kling
MA, Munson PJ, et al. Pronounced and
sustained central hypernoradrenergic function in major depression with
melancholic features: relation to hypercortisolism and corticotropin-releasing
hormone. Proc Natl Acad Sci U S A.
2000;97(1):325-30. [104] Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999;85(3):275-91. [105]Peet M, Murphy B, Shay J, et al. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998;43(5):315-19. [106] Adams PB, Lawson S, Sanigorski, A, et al. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids. 1996;31 Suppl:S157-61. [107] Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot Essent Fatty Acids. 1999;60:329-37. [108] Hakkarainen R, Partonen T, Haukka J, et al. Food and nutrient intake in relation to mental wellbeing. Nutr J. 2004;3:14. [109] Jacka EN, Pasco JA, Henry MJ, et al. Dietary omega-3 fatty acids and depression in a community sample. Nutr Neurosci. 2004;7(2):101-6. [110] Korsch BM, Gozzi EK, Francis V. Gaps in
doctor-patient communication. I: Doctor-patient interaction and patient satisfaction.
Pediatrics. 1968;42:855-71. [111] Williams GH, Wood PHN. Common-sense beliefs about
illness: a mediating role for the doctor. Lancet. 1986;328:1435-37. [112] Eisenberg L. What makes persons “patients” and
patients “well.” Am J Med. 1980;69(2):277-86. [113] Gautam SC, Pindolia KR, Noth CJ, et al. Chemokine gene expression in bone marrow stromal cells: downregulation with sodium salicylate. Blood. 1995;86(7):2541-50. [114] Giggs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and anti-inflammatory activity. Proc Nat Acad Sci U S A. 1987;84:1417-20. [115] Blacklock CJ, Lawrence JR, Wiles D, et al. Salicylic
acid concentrations in the serum of subjects not taking aspirin: comparison of
salicylic acid concentrations in the serum of vegetarians, non-vegetarians and
patients taking low-dose aspirin. J Clin Pathol. 2001;54:553-55. [116] Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr. 2002:56 Suppl 3:S14-19. [117] Chambrier C, Bastard JP, Rieusset J, et
al. Eicosapentaenoic acid induces mRNA expression of
peroxisome proliferator-activated receptor gamma. Obes Res.
2002;10:518-25. [118] Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha
ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38
mitogen-activated protein kinase. Hypertension. 2000;36:851-55. [119] Chalon S, Vancassel S, Zimmer L, et al. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic
neurotransmission. Lipids.
2001;36:937-44. [120] Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495-505. [121] Belch JJF, Ansell D, Madhok R, et
al. Effects of altering dietary essential fatty acids on requirements
for non-steroidal anti-inflammatory drugs in patients with rheumatoid
arthritis: a double blind placebo controlled study. Ann Rheum Dis. 1988;47:96-104. [122] Stenson WF, Cort D, Rodgers J, et al. Dietary supplements with fish oil in ulcerative colitis. Ann Intern Med. 1992;116:609-14. [123] Gapinski JP, VanRuiswyk V, Heudebert GR, Schectman GS. Preventing restenosis with fish oils following coronary angioplasty. Arch Int Med. 1993;153:1595-1601. [124] Nestares T, Lopez-Jurado M, Urbano G, et al. Effects of lifestyle modification and lipid intake variations on patients with peripheral vascular disease. Int J Vitam Nutr Res. 2003;73(5):389-98. [125] Harel
Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation
with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in
adolescents. Am J Obstet Gynecol. 1996;174(4):1335-38. [126] Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet. 1993;342:465-69. [127] McCaren T, Hitzeman R, Smith R, et al. Amelioration of severe migraine by fish oil (n-3) fatty acids. Am J Clin Nutr. 1985;41:874. [128] Yao JK, Magan S, Sonel AF, et al. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2004;71(3):171-76. [129] Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic
acid) supplementation for residual symptoms and cognitive impairment in
schizophrenia. Am J Psychiatry. 2001;158(12):2071-74. [130] Mayser P, Mayer K, Mahloudjian M, et al. A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis. J Parenter Enteral Nutr. 2002;26(3):151-58. [131] Nordvik I, Myhr
KM, Nyland H, Bjerve KS. Effect of
dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand. 2000;102(3)143-49. [132] Bates D, Cartlidge NEF, French JM, et. al. A double-blind controlled trial of n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52:18-22. [133] Prasad AS. Zinc in growth and development and spectrum of human zinc deficiency. J Am Coll Nutr. 1988;7(5):377-84. [134] Stevens LJ, Zentall SS, Deck JL, et al, Essential
fatty acid metabolism in boys with attention deficit hyper activity disorder.
Amer J Clin Nutr. 1995;62:761–68. [135] Stevens LJ, Zentall SS, Abate ML, et al. Omega-3 fatty acids in boys with behavior, learning and health problems. Physiol Behav. 1996;59:75-90. [136] Galland L. Power Healing. New York: Random House, 1997, pp. 156-162. [137] Cleland LG, Proudman SM, Hall C, et al, A biomarker of n-3 compliance in patients taking fish oil for rheumatoid arthritis. Lipids. 2003; 38: 419-24. This article is provided for general educational purposes only and is not intended to constitute (i) medical advice or counseling, (ii) the practice of medicine or the provision of health care diagnosis or treatment, (iii) the creation of a physician--patient relationship, or (iv) an endorsement, recommendation or sponsorship of any third party product or service by the sender or the sender's affiliates, agents, employees, or service providers. If you have or suspect that you have a medical problem, contact your doctor promptly. |
Terms of Use Agreement | ©2006 - 2008 Renaissance Workshops Ltd.
|